Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-18

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Severe obesity is associated with considerable reduction of wellbeing and life expectancy. People living with severe obesity tend to die 8 to 10 years earlier. Preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity. The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

NCT03115424

Obesity

COMPLETED PHASE3

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

NCT06278285

Obesity

RECRUITING NA

Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients

NCT04325581

Weight Loss

COMPLETED PHASE3

Impact GLP-1 Agonists Following Bariatric

NCT06132477

Morbid Obesity Metabolic Syndrome Diabetes Mellitus +2 more

RECRUITING PHASE4

Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults

NCT02654665

Non-alcoholic Fatty Liver Disease (NAFLD) Weight Loss Non-alcoholic Steatohepatitis (NASH)

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective:

Determine liraglutide effectiveness for preoperative weight-loss in patients with severe obesity undergoing bariatric-metabolic surgery.

Methods:

It is a single center, quasi-experimental prospective before-and-after study. All patients were assigned the same pharmacological treatment with liraglutide, initiating dosing with 0.6 mg per day escalating 0.6 mg every week up to 3.0 mg. The treatment dose was delivered once daily via subcutaneous injection for 3 months (12 weeks). Weight-loss and percentage weight-loss was evaluated monthly using bioelectric impedance (BIA) final result at week 12.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Weight Loss Bariatric Surgery Candidate Obesity, Morbid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

quasi-experimental prospective before-and-after study.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with morbid obesity in bariatric surgery preparation protocol

All patients with body mass index \>48 kg/m2 in preoperative protocol for bariatric surgery using liraglutide for preoperative weight loss

Group Type EXPERIMENTAL

Liraglutide injection

Intervention Type DRUG

Liraglutide (GLP-1 analog) injection during 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liraglutide injection

Liraglutide (GLP-1 analog) injection during 3 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with BMI greater than 48 kg/m2 in pre-surgical protocol for bariatric surgery of the Bariatric and Metabolic Surgery Unit of the Civil Hospital of Guadalajara "Dr. Juan I. Menchaca

Exclusion Criteria

* Patients under 18 years of age or over 65 years of age.

* Pregnant patients.
* Patients who do not agree to give their consent and take part in the study.
* Patients with allergy to liraglutide, multiple endocrine neoplasia type 2 and medullary thyroid cancer, gallstones.

Removal:

* Patients who decide to abandon the study.
* Patients who do not follow the instructions or do not adhere to the treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No